PL2209527T3 - Kompozycje farmaceutyczne zawierające probiotyki L.acidophilus i Bifidobacterium lactis do stosowania w leczeniu zaburzenia czynnościowego jelit - Google Patents

Kompozycje farmaceutyczne zawierające probiotyki L.acidophilus i Bifidobacterium lactis do stosowania w leczeniu zaburzenia czynnościowego jelit

Info

Publication number
PL2209527T3
PL2209527T3 PL08838386T PL08838386T PL2209527T3 PL 2209527 T3 PL2209527 T3 PL 2209527T3 PL 08838386 T PL08838386 T PL 08838386T PL 08838386 T PL08838386 T PL 08838386T PL 2209527 T3 PL2209527 T3 PL 2209527T3
Authority
PL
Poland
Prior art keywords
acidophilus
treatment
pharmaceutical compositions
bifidobacterium lactis
functional bowel
Prior art date
Application number
PL08838386T
Other languages
English (en)
Inventor
Gregory Leyer
Arthur Ouwehand
Original Assignee
Dupont Nutrition Biosci Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40549819&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2209527(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dupont Nutrition Biosci Aps filed Critical Dupont Nutrition Biosci Aps
Publication of PL2209527T3 publication Critical patent/PL2209527T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Immunology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
PL08838386T 2007-10-11 2008-10-08 Kompozycje farmaceutyczne zawierające probiotyki L.acidophilus i Bifidobacterium lactis do stosowania w leczeniu zaburzenia czynnościowego jelit PL2209527T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97918707P 2007-10-11 2007-10-11
EP08838386A EP2209527B1 (en) 2007-10-11 2008-10-08 Pharmaceutical compositions comprising L. acidophilus and Bifidobacterium lactis for use in the treatment of functional bowel disorder
PCT/US2008/079177 WO2009048934A2 (en) 2007-10-11 2008-10-08 Probiotics for use in relieving symptoms associated with gastrointestinal disorders

Publications (1)

Publication Number Publication Date
PL2209527T3 true PL2209527T3 (pl) 2013-03-29

Family

ID=40549819

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08838386T PL2209527T3 (pl) 2007-10-11 2008-10-08 Kompozycje farmaceutyczne zawierające probiotyki L.acidophilus i Bifidobacterium lactis do stosowania w leczeniu zaburzenia czynnościowego jelit

Country Status (10)

Country Link
US (1) US9055763B2 (pl)
EP (1) EP2209527B1 (pl)
JP (2) JP5758629B2 (pl)
CN (1) CN101998834B (pl)
AU (2) AU2008310961B2 (pl)
CA (1) CA2702293C (pl)
DK (1) DK2209527T3 (pl)
ES (1) ES2399775T3 (pl)
PL (1) PL2209527T3 (pl)
WO (1) WO2009048934A2 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2962158B2 (ja) 1994-09-08 1999-10-12 三菱電機株式会社 レーダ信号処理装置
FR2955774A1 (fr) 2010-02-02 2011-08-05 Aragan Preparation destinee a traiter l'exces ponderal et les desordres associes et applications de ladite preparation
JP6781887B2 (ja) * 2014-02-28 2020-11-11 株式会社明治 機能性消化管障害予防及び／又は改善剤
EP3524051A1 (en) 2018-02-12 2019-08-14 DuPont Nutrition Biosciences ApS Matricial microencapsulation compositions
BR112020018047A2 (pt) * 2018-03-05 2020-12-22 Bio-K Plus International Inc. Métodos para o alívio de um distúrbio gastrointestinal e da síndrome do intestino irritável e para melhorar a qualidade de vida de um indivíduo que sofre de síndrome do intestino irritável, método alternativo à terapia com fármacos para a prevenção e/ou tratamento da síndrome do intestino irritável, composições para o alívio de um distúrbio gastrointestinal e da síndrome do intestino irritável, e, uso de uma combinação
EP3821718A1 (en) * 2019-11-15 2021-05-19 DuPont Nutrition Biosciences ApS Probiotics for lactose intolerance
US11742069B2 (en) * 2021-02-01 2023-08-29 Kpn Innovations, Llc. Systems and methods for generating a nociception nourishment program
US20250295712A1 (en) * 2022-02-09 2025-09-25 The Regents Of The University Of Michigan Compositions and methods for modulating gut microbiomes
CN116746683B (zh) * 2023-08-01 2024-11-15 河北源民生物科技有限公司 防消化不良胀气、促吸收的动物双歧杆菌乳亚种bal-28及发酵产物、菌群cw和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4196132B2 (ja) * 1997-12-22 2008-12-17 小林製薬株式会社 脱ガス組成物
IT1304170B1 (it) * 1998-12-15 2001-03-08 Novartis Nutrition Ag Composti organici
EP1384483A1 (en) * 2002-07-23 2004-01-28 Nestec S.A. Probiotics for treatment of irritable bowel disease (IBS) through improvement of gut neuromuscular function
US7740838B2 (en) 2002-12-05 2010-06-22 Danisco A/S Bacterial composition and its use
FR2848115B1 (fr) * 2002-12-05 2005-03-25 Rhodia Chimie Sa Composition de bacteries et son utilisation
FR2875406B1 (fr) * 2004-09-21 2007-01-05 Danisco Souche de lactobacillus acidophilus ayant des proprietes analgesiques au niveau du systeme gastro-intestinal
US20060093592A1 (en) * 2004-10-04 2006-05-04 Nutracea Synbiotics
ITMI20042189A1 (it) * 2004-11-16 2005-02-16 Anidral Srl Composizione a base di batteri probiotici e suo uso nella prevenzione e-o nel trattamento di patologie e-o infezioni respiratorie e nel miglioramento della funzionalita' intestinale
WO2006097949A1 (en) * 2005-03-16 2006-09-21 Actial Farmacêutica, Lda. Mixture of at least 6 species of lactic acid bacteria and/or bifidobacteria in the manufacture of sourdough
EP1981516B1 (en) 2006-01-27 2018-08-08 DuPont Nutrition Biosciences ApS Use of probiotic microorganisms for the treatment and prevention of obesity and related disorders

Also Published As

Publication number Publication date
HK1146914A1 (en) 2011-07-22
AU2008310961A1 (en) 2009-04-16
US9055763B2 (en) 2015-06-16
AU2014210581A1 (en) 2014-08-28
JP5674741B2 (ja) 2015-02-25
DK2209527T3 (da) 2013-03-18
JP2013040186A (ja) 2013-02-28
WO2009048934A2 (en) 2009-04-16
ES2399775T3 (es) 2013-04-03
CN101998834B (zh) 2017-05-10
CA2702293C (en) 2016-08-02
EP2209527A2 (en) 2010-07-28
US20110033423A1 (en) 2011-02-10
CN101998834A (zh) 2011-03-30
JP2011501664A (ja) 2011-01-13
EP2209527B1 (en) 2012-12-05
AU2014210581B2 (en) 2016-07-14
JP5758629B2 (ja) 2015-08-05
WO2009048934A3 (en) 2009-10-29
AU2008310961B2 (en) 2014-08-28
CA2702293A1 (en) 2009-04-16

Similar Documents

Publication Publication Date Title
PL1773361T3 (pl) Kompozycje oparte na bakteriach probiotycznych i ich zastosowanie w profilaktyce i/lub leczeniu patologii i/lub zakażeń układu oddechowego oraz poprawie funkcji jelit
PL2219658T3 (pl) Kompozycja oparta na bakteriach probiotycznych w połączeniu z prebiotykiem i jej zastosowanie w zapobieganiu i/lub leczeniu schorzeń oddechowych i/lub infekcji oraz do polepszenia funkcjonalności jelit
PL1981516T3 (pl) Zastosowanie mikroorganizmów probiotycznych w leczeniu i zapobieganiu otyłości i pokrewnym zaburzeniom
AP2957A (en) New antibodies specific of the Beta-amyloid peptides and their uses as diagnostic agents or drugs
IL206080A (en) A pharmaceutical preparation for the treatment and / or prevention of bone and joint disease
PL2435056T3 (pl) Lactobacillus pentosus wytwarzający bakteriocyny i jego zastosowanie w kompozycjach żywnościowych i farmaceutycznych
ZA200905886B (en) Methods and kits for administering probiotics
IL199045A0 (en) Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases
EP2007385A4 (en) CARDIOVASCULAR COMPOSITION AND ITS USE FOR THE TREATMENT OF MORBUS ALZHEIMER
IL216599A (en) 4,1-Bi-Conjugated Phthalazine History, Pharmaceuticals Containing Them and Their Use in Cancer Treatment
IL197240A0 (en) Wnt antagonists and their use in the diagnosis and treatment of wnt-mediated disorders
IL220613B (en) Use of antibiotics and a probiotic formulation in the preparation of a drug for the treatment of inflammatory bowel disease
PL2066351T3 (pl) Przeciwciała ludzkie wiążące CXCR4 i ich wykorzystanie
PL2802333T3 (pl) Lactobacillus rhamnosus i Bifidobacterium animalis subsp. lactis do stosowania dla zapobiegania lub leczenia zakażeń górnych dróg oddechowych
GB0720983D0 (en) Catalyst particles their preparation and use
EP2087094A4 (en) LACTOBACILLUS FERMENTUM ESS-1, DSM17851 AND ITS USE IN THE TREATMENT AND / OR PREVENTION OF CANDIDOSIS AND URINARY TRACT INFECTIONS
PL2068899T3 (pl) Lactobacillus acidophilus do zastosowania w zmniejszaniu częstości występowania i czasu trwania zakażeń dróg oddechowych
GB0722996D0 (en) Depsipeptides and their therapeutic use
ZA201003037B (en) Use of 3, 11b-cis-dihydrotettabenazine in the treatment of multiple sclerosis and autoimmune myelitis
DK2209527T3 (da) Farmaceutiske sammensætninger omfattende L-acidophilus og Bifidobacterium lactis til anvendelse i behandlingen af funktionel tarmsygdom
PL2308566T3 (pl) Zastosowanie doustnie podawanych probiotycznych bifidobakterii w celu uzyskania korzyści dla ludzkiego piękna
GB2452696B (en) 3-(2',2'-dimethylpropanoylamino)-tetrahydropyridin-2-one and its use in pharmaceutical compositions
GB0908868D0 (en) Depsipeptide and their therapeutic use
IL195155A (en) Dosage form for delayed glucocorticoid release and its use in the treatment of rheumatic diseases
IL201426A0 (en) Drug combination and its use in the treatment of muscle loss